Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024129 | 0.88 | GRIN2B (0.34) | GRIN2BALDH1A1PKMCDK12 | |
| SCHEMBL5025529 | 0.80 | TAS2R14 (0.40) | GRIN2BALDH1A1PKMACACBLMNA | |
| SCHEMBL5025534 | 0.80 | TAS2R14 (0.40) | GRIN2BALDH1A1PKMACACBLMNA | |
| SCHEMBL5030212 | 0.76 | TAS2R14 (0.38) | GRIN2BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14174989 | 0.71 | L3MBTL1 (0.40) | ALDH1A1L3MBTL1LMNAHTTSMN1; SMN2 | |
| SCHEMBL5026543 | 0.71 | TAS2R14 (0.35) | ALDH1A1DRD2DRD3LMNASMN1; SMN2 | |
| SCHEMBL5026538 | 0.71 | TAS2R14 (0.35) | ALDH1A1DRD2DRD3LMNASMN1; SMN2 | |
| SCHEMBL5030010 | 0.68 | HTT (0.40) | GRIN2BALDH1A1L3MBTL1LMNAHTT | |
| SCHEMBL5030014 | 0.68 | HTT (0.40) | GRIN2BALDH1A1L3MBTL1LMNAHTT | |
| SCHEMBL5762331 | 0.68 | GRIN2B (0.32) | GRIN2BACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442791-B2 | Aminoalkylamide substituted cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1667962-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028427-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | LSS, CYP51A1, CYP46A1 | GRIN2B 4512/4885CRHR1 4108/4885ALDH1A1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.